← Leaderboards
Michael S Zamloot
Cassava Sciences, Inc
$1,214,493
Attributed
$2,328,986
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,328,986 · 2
By mechanism
R44$2,228,986 · 1
R43$100,000 · 1
Top collaborators
- Shawn Kucera2 shared
Most similar at Cassava Sciences, Inc
Same institution · by research overlap
- Lindsay H Burns$16,572,741
- Shawn Kucera$1,114,493
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationAddictionAbsorptionAdhesivesAnalytical MethodArtificial MembranesBaseAdhesionsChildClinical LotClinical TrialsConformerCrystallinityCrystallizationDangerousnessDeglutitionDermalDesignDissociationDoseDrug KineticsEnhancersEnsureExcipients
Grant awards (3)
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch$1,879,039
R44 · FY2019 · DA
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch$349,947
R44 · FY2017 · DA
Abuse-deterrent sustained-release hydromorphone$100,000
R43 · FY2006 · DA · contact PI